Novinky z tohtoročného najvýznamnejšieho stretnutia onkológov 2018

Táto publikácia prináša súhrn toho najdôležitejšieho, čo sa preberalo na konferencii Americkej spoločnosti klinickej onkológie, ktorá prebehla v júni 2018 v americkom Chicagu. Nájdete tu zhrnutia sekcií: genitourinárne malignity, melanóm, nádory gastrointestinálneho traktu, rakovina pľúc, gynekologické nádory a rakovina prsníka. Pôvodné informácie doplňujú abstrakty vybraných prednášok.

Obsah

SPRÁVA Z VÝROČNEJ KONFERENCIE AMERICKEJ ONKOLOGICKEJ SPOLOČNOSTI 2018 Mária Rečková
Adjuvant Docetaxel Fails to Improve DFS for Intermediate- or High-Risk Prostate Cancer Leah Lawrence
A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high-risk prostate cancer: Results of SPCG-13 trial
Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC)
First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt)
Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC)
Accuracy of 68Ga-PSMA11 PET/CT on recurrent prostate cancer: Preliminary results from a phase 2/3 prospective trial
Léčba metastazujícího melanomu na ASCO 2018 Ivana Krajsová
Neoadjuvant Nivolumab Leads to Tumor Regression in Resectable Merkel Cell Carcinoma Muriel Cunningham
Nivolumab (Nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358
Four-Year Data Show Durable Effect of Pembrolizumab in Advanced Melanoma Muriel Cunningham
Characterization of complete responders to combination nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with advanced, unresectable melanoma
Anti-PD1 antibodies in late elderly advanced melanoma patients: A retrospective multicentre study
Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma
Najvýznamnejšie klinické správy z konferencie ASCO 2018 v problematike nádorov gastrointestinálneho traktu Radovan Barilla
High-Dose Acid Suppression for Preventing Esophageal Adenocarcinoma in Patients With Metaplasia Tim Donald
Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: Efficacy and safety in the phase III randomized factorial ASPECT trial
High-Dose Acid Suppression for Preventing Esophageal Adenocarcinoma in Patients With Metaplasia Dave Levitan
KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer
Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas
Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial
Long-term results of the ADORE trial: Adjuvant oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) versus 5-fluorouracil and leucovorin (FL) after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer
First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study
Karcinóm pľúc na ASCO 2018 Peter Beržinec
Frontline Pembrolizumab and Chemotherapy a New Standard of Care in Metastatic Squamous NSCLC Kara Nyberg
Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC)
Pembrolizumab Improves Survival, Reduces Toxicity Over Chemotherapy in Low PD-L1–Expressing NSCLC Dave Levitan
Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study
Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026
4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001
A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER
Správa z ASCO 2018 – Gynekologické malignity Branislav Bystrický
Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602
A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study
Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Interim analysis of a phase 2, open-label, randomized, multicenter trial
ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial canceR
Comparison of different adjuvant therapy after radical surgery in early stage cervical carcinoma: A 3-arm randomized control study
KARCINOM PRSU NA ASCO 2018 Katarína Petráková
TAILORx: Many Women With Early Breast Cancer Can Avoid Chemotherapy Tim Donald
TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score
Persephone Demonstrates Noninferiority of Shorter Duration Adjuvant Trastuzumab in HER2-Positive Breast Cancer
PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results
De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study
Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo-controlled D-CARE study
Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study

Anotácia

Obsah

Tiráž

Česká diabetologie

Cystická fibróza

Ekonomie ve zdravotnictví

ESO Journal

News

Podpůrná léčba

Case Reports

Event Reports

Kongresové materiály

Albertova sbírka

Partneři projektu

Webinář

Webinář

Ak máte užívateľský účet, môžete sa prihlásiť tu

Novinky z tohtoročného najvýznamnejšieho stretnutia onkológov 2018

Anotácia

Obsah

Tiráž

Česká diabetologie

Cystická fibróza

Ekonomie ve zdravotnictví

ESO Journal

News

Podpůrná léčba

Case Reports

Event Reports

Kongresové materiály

Albertova sbírka

Partneři projektu

Webinář

Webinář